Shares of China Biologic Products Inc. (NASDAQ:CBPO) were down 2.2% during mid-day trading on Friday . The stock traded as low as $118.67 and last traded at $118.91, with a volume of 81,659 shares changing hands. The stock had previously closed at $121.60.

Several analysts recently issued reports on CBPO shares. Jefferies Group restated a “buy” rating on shares of China Biologic Products in a research report on Saturday, June 4th. Zacks Investment Research lowered shares of China Biologic Products from a “hold” rating to a “sell” rating in a research report on Friday, May 6th. Finally, Credit Suisse Group AG upgraded shares of China Biologic Products from a “neutral” rating to an “outperform” rating in a research report on Tuesday, July 5th.

The firm has a 50-day moving average price of $110.63 and a 200-day moving average price of $115.63. The stock has a market capitalization of $3.17 billion and a price-to-earnings ratio of 35.71.

China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.06. The firm earned $85.60 million during the quarter, compared to the consensus estimate of $74 million. The business’s quarterly revenue was up 21.6% on a year-over-year basis. Equities research analysts anticipate that China Biologic Products Inc. will post $4.29 EPS for the current year.

In other news, Director Wp X. Biologics Llc sold 2,775,000 shares of the firm’s stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $111.00, for a total value of $308,025,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Ming Yin sold 19,618 shares of the firm’s stock in a transaction dated Friday, May 20th. The shares were sold at an average price of $113.64, for a total transaction of $2,229,389.52. Following the completion of the sale, the vice president now owns 51,419 shares in the company, valued at $5,843,255.16. The disclosure for this sale can be found here.

Several hedge funds have recently added to or reduced their stakes in the stock. Employees Retirement System of Texas purchased a new stake in China Biologic Products during the fourth quarter worth $2,846,000. WCM Investment Management CA boosted its stake in China Biologic Products by 22.8% in the fourth quarter. WCM Investment Management CA now owns 60,753 shares of the biopharmaceutical company’s stock worth $8,655,000 after buying an additional 11,282 shares in the last quarter. Finally, Russell Frank Co boosted its stake in China Biologic Products by 69.1% in the fourth quarter. Russell Frank Co now owns 14,104 shares of the biopharmaceutical company’s stock worth $1,993,000 after buying an additional 5,764 shares in the last quarter.

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.